PPARG and prostate cancer: For example, among threePPARγ agonists, ciglitazone, 9-HODE, and 13-HODE, only 9-HODE induced apoptosisin U937 cells [38], 15d-Δ12,14-PGJ2,but not various other PPARγ ligands, reduced EGFR expression in squamous carcinoma cells[99], 15d-Δ12,14-PGJ2,but not troglitazone, inhibited the stimulated induction of MHC class IImolecules in retinal pigmented epithelial cells [112], and DHA, but not EPA, stimulatedthe target gene, syndecan 1 to inhibit the proliferation and induce apoptosisin breast and prostate cancer cell lines [75, 76, 96].